68ga-lnc1007
Cancer Patients
Yantai LNC Biotechnology Singapore PTE. LTD.radiopharmaceuticalPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1411 Active assets in the Cancer Patients cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
PROPOFOL Hong Kong Children's Hospital | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
68ga-lnc1007 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →